PositiveID’s Patented M-BAND is the Only Successful System to Emerge From Department of Homeland Security’s Bioagent Autonomous Networked Detector (“BAND”) Program and Only System of Its Kind Demonstrated in the Field Under That Program

DELRAY BEACH, Fla., March 13, 2012 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID”) (OTCBB:PSID), a developer of molecular diagnostic systems for bio-threat detection, announced today that its M-BAND (Microfluidic-Bioagent Autonomous Networked Detector) system is well positioned to take part in the Department of Homeland Security’s (“DHS”) $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS Science and Technology (“S&T”) BAND Program. PositiveID’s patented M-BAND biodetector was developed under a competitive award from DHS S&T, and M-BAND was the only successful system to emerge from the BAND program.

M-BAND, protected by United States Patent No. 7,705,739 B2 for an Integrated Airborne Substance Collection and Detection System, was developed by PositiveID’s Microfluidic Systems (“MFS”) subsidiary under six years of funding from the federal government.

M-BAND is a bioaerosol monitor with fully integrated modular systems including sample collection, purification and detection modules. Each module is independently functional and adaptable. M-BAND runs autonomously for up to 30 days, continuously analyzing air samples for the detection of bacteria, viruses, and toxins with results in as little as three hours. Results from individual instruments are reported via a secure wireless network in real time to give an accurate and up to date status for fielded instruments in aggregate. Also as part of the BAND Program, PositiveID developed, validated and implemented its own biological assays for use on the M-BAND system and research laboratories. (www.PSIDMBA.com).

The M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation. M-BAND has been designed and field tested to operate continuously for 30 days unattended between scheduled services. It also operates using industry gold-standard TaqMan® PCR (polymerase chain reaction) chemistry.

William J. Caragol, Chairman and CEO of PositiveID, stated, “We believe M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally. We further believe that M-BAND has significant benefits that set this technology apart and put us in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity.”

About PositiveID Corporation

PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID’s future expectations, including the likelihood that PositiveID’s M-BAND system is well positioned to take part the DHS $3.1 billion BioWatch Gen-3 opportunity, expected to be released in the first half of 2012, and is the only system of its kind that was demonstrated in the field under the DHS S&T BAND Program; the likelihood that M-BAND was the only successful system to emerge from the BAND program; the likelihood that the M-BAND instrument offers a number of advantages including decreased consumable and operating costs, a small footprint, a closed operating environment and significant flexibility of operation; the likelihood that M-BAND is the only system of its kind that has been successfully field tested indoors and outdoors, both domestically and internationally; the likelihood that M-BAND has significant benefits that set this technology apart and put PositiveID in a strong position to participate with large partners in the $3.1 billion BioWatch opportunity; and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include PositiveID’s ability to successfully participate in the $3.1 billion BioWatch opportunity; as well as certain other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: Allison Tomek
561-805-8000
atomek@positiveidcorp.com

Source: Globe Newswire